Endometrial Cancer（EC） - Medical Tourism & Treatment Guide in China

Endometrial carcinoma, the most common gynecologic malignancy in developed countries, originates from the glandular epithelium of the endometrium. Risk factors include unopposed estrogen exposure (e.g., obesity, polycystic ovary syndrome, estrogen-only hormone therapy), nulliparity, late menopause, and hereditary syndromes such as Lynch syndrome. Most cases present with abnormal uterine bleeding—particularly postmenopausal bleeding—and are diagnosed via transvaginal ultrasound followed by endometrial biopsy or hysteroscopy-guided sampling. Histologically, endometrioid adenocarcinoma (Type I) accounts for approximately 80% of cases and is typically low-grade, estrogen receptor–positive, and associated with favorable prognosis when detected early. Less common but more aggressive subtypes include serous, clear cell, and carcinosarcoma (Type II), often requiring multimodal management. Staging follows the FIGO system and guides treatment: surgical staging (total hysterectomy, bilateral salpingo-oophorectomy, pelvic/para-aortic lymphadenectomy) remains the cornerstone; adjuvant radiotherapy, chemotherapy (e.g., carboplatin-paclitaxel), or hormonal therapy may be indicated based on histopathologic risk stratification.

China offers compelling advantages for international patients seeking endometrial cancer care. Leading oncology centers—such as Fudan University Shanghai Cancer Center and Peking Union Medical College Hospital—employ multidisciplinary tumor boards with subspecialized gynecologic oncologists, advanced robotic-assisted laparoscopic surgery (da Vinci Xi), intraoperative fluorescence imaging, and next-generation sequencing for molecular profiling. Five-year relative survival rates for Stage I disease exceed 90%, consistent with global benchmarks, while complex case outcomes reflect robust clinical experience—over 12,000 endometrial cancer surgeries performed annually across Tier-3 hospitals. Crucially, comprehensive treatment—including genomic testing, targeted therapies, and intensity-modulated radiation—costs 40–60% less than in the US or Western Europe, without compromising evidence-based protocols or accreditation standards (JCI- or CNAS-certified facilities). As a dedicated medical tourism agency, we facilitate seamless access: verifying physician credentials, coordinating appointments at vetted hospitals, providing itemized, transparent pricing in advance, arranging medical visas, interpreters, accommodation, and post-treatment follow-up—all tailored to individual clinical and logistical needs.